The Massachusetts-based biotech company led by CEO Stéphane Bancel went from relative obscurity to the Wall Street spotlight when its mRNA-based COVID-19 vaccine, developed with scientists from the U.S. National Institute of Allergy and Infectious Diseases, became the first in the U.S. to start human testing last March. The vaccine’s December 2020 greenlight by the U.S. Food and Drug Administration—and its subsequent worldwide distribution—vindicates the company’s focus on using mRNA genetic material to teach the human body to fight off COVID-19. Millions have received the shot, and Moderna is ramping up production to meet continued worldwide demand.
More Must-Reads from TIME
- L.A. Fires Show Reality of 1.5°C of Warming
- Home Losses From L.A. Fires Hasten ‘An Uninsurable Future’
- The Women Refusing to Participate in Trump’s Economy
- Bad Bunny On Heartbreak and New Album
- How to Dress Warmly for Cold Weather
- We’re Lucky to Have Been Alive in the Age of David Lynch
- The Motivational Trick That Makes You Exercise Harder
- Column: No One Won The War in Gaza
